X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Pulmocide’s opelconazole is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pictet Alternative Advisors
Deal Size: $147.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 06, 2022
Details:
The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infections in lung transplant.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2021
Details:
Pulmocide’s lead product is opelconazole (PC945), a novel antifungal therapy specifically designed for inhaled use to maximize the amount of drug in the lung and spare systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Proceeds from the financing will primarily be used to advance the Company’s lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $92.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
